Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BioCryst Pharmaceuticals (BCRX) stocks in Canada

Learn how to easily invest in BioCryst Pharmaceuticals stocks.

BioCryst Pharmaceuticals is a biotechnology business based in the US. BioCryst Pharmaceuticals stocks (BCRX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $16.25 – an increase of 0.76% over the previous week. BioCryst Pharmaceuticals employs 246 staff and has a trailing 12-month revenue of around $114 million.

How to buy shares in BioCryst Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BCRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

BioCryst Pharmaceuticals stock price (NASDAQ:BCRX)

Use our graph to track the performance of BCRX stocks over time.

BioCryst Pharmaceuticals shares at a glance

Information last updated 2022-01-23.
Latest market close$14.65
52-week range$8.37 - $18.48
50-day moving average $12.98
200-day moving average $14.31
Wall St. target price$20.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.28

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy BioCryst Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

BioCryst Pharmaceuticals price performance over time

Historical closes compared with the close of $14.65 from 2022-01-25

1 week (2022-01-15) N/A
1 month (2021-12-23) 5.24%
3 months (2021-10-26) -4.75%
6 months (2021-07-26) -15.07%
1 year (2021-01-26) 59.93%
2 years (2020-01-24) 421.35%
3 years (2019-01-25) 50.72%
5 years (2017-01-26) 127.13%

BioCryst Pharmaceuticals financials

Revenue TTM $114 million
Gross profit TTM $-106,828,000
Return on assets TTM -51.75%
Return on equity TTM -1925.37%
Profit margin -198.88%
Book value $0.19
Market capitalisation $2.5 billion

TTM: trailing 12 months

BioCryst Pharmaceuticals share dividends

We're not expecting BioCryst Pharmaceuticals to pay a dividend over the next 12 months.

BioCryst Pharmaceuticals share price volatility

Over the last 12 months, BioCryst Pharmaceuticals's shares have ranged in value from as little as $8.37 up to $18.48. A popular way to gauge a stock's volatility is its "beta".

BCRX.US volatility(beta: 2.48)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioCryst Pharmaceuticals's is 2.484. This would suggest that BioCryst Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

BioCryst Pharmaceuticals overview

BioCryst Pharmaceuticals, Inc. , a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co. , Ltd.

Stocks similar to BioCryst Pharmaceuticals

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site